AI brief of an SEC Form 8-K · Charles River Laboratories (CRL)

Charles River Adds Four Elliott-Backed Directors, Starts Strategic Review

Neutral Impact 4 of 5 shareholder Written later

Charles River Laboratories entered a Cooperation Agreement with activist investor Elliott Investment Management, which will add four new directors after the May 20, 2025 annual meeting and launch a comprehensive strategic review of the business. Four incumbent directors will not stand for re-election, and the board will be limited to 11 members while the agreement is in effect.

Key points

  • Steven Barg, Abe Ceesay, Mark Enyedy and Paul Graves join the board after the May 20, 2025 annual meeting, each for a term ending at the 2026 annual meeting.
  • Robert Bertolini, Deborah Kochevar, George Massaro and Richard Wallman will not stand for re-election at the 2025 annual meeting.
  • The Strategic Planning and Capital Allocation Committee will review the business and examine alternatives to enhance long-term stockholder value, then report to the full board.
  • The filing gives no financial results or guidance; the press release describes Elliott as the company's largest investor.

The filing

CompanyCharles River Laboratories (CRL)
Form8-K, current report
Filed with the SECMay 7, 2025, 7:15 AM ET
Accession number0000950103-25-005798

Items reported: 1.01 Material Definitive Agreement5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:11 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.